Achieve Life Sciences (NASDAQ:ACHV) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $4.75 and traded as high as $4.90. Achieve Life Sciences shares last traded at $4.84, with a volume of 36,588 shares changing hands.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Oppenheimer restated an “outperform” rating and issued a $11.00 target price on shares of Achieve Life Sciences in a report on Thursday, August 15th. Raymond James initiated coverage on shares of Achieve Life Sciences in a report on Friday, September 27th. They issued a “strong-buy” rating and a $20.00 target price on the stock.

Achieve Life Sciences Trading Up 2.8 %

The company has a quick ratio of 4.56, a current ratio of 4.56 and a debt-to-equity ratio of 0.21. The firm’s 50-day moving average price is $4.64 and its 200 day moving average price is $4.75. The company has a market capitalization of $166.21 million, a P/E ratio of -4.36 and a beta of 1.56.

Achieve Life Sciences (NASDAQ:ACHV) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.03). During the same period in the prior year, the company earned ($0.43) EPS. As a group, equities research analysts predict that Achieve Life Sciences, Inc. will post -1.03 earnings per share for the current year.

Institutional Investors Weigh In On Achieve Life Sciences

Institutional investors have recently added to or reduced their stakes in the company. CVI Holdings LLC bought a new stake in Achieve Life Sciences in the 1st quarter worth about $2,578,000. Vanguard Group Inc. grew its position in Achieve Life Sciences by 56.6% in the 1st quarter. Vanguard Group Inc. now owns 948,441 shares of the biopharmaceutical company’s stock worth $4,311,000 after purchasing an additional 342,731 shares in the last quarter. Virtu Financial LLC bought a new stake in Achieve Life Sciences in the 1st quarter worth about $59,000. Renaissance Technologies LLC grew its position in Achieve Life Sciences by 134.2% in the 2nd quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 14,360 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in Achieve Life Sciences in the 2nd quarter worth about $69,000. 33.52% of the stock is owned by institutional investors.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.